标题
Elbasvir and grazoprevir for the treatment of hepatitis C
作者
关键词
-
出版物
Expert Review of Anti-Infective Therapy
Volume -, Issue -, Pages 1-11
出版商
Informa UK Limited
发表日期
2021-01-14
DOI
10.1080/14787210.2021.1874351
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Enhancement of thermo-mechanical stability for nanocomposites containing plasma treated carbon nanotubes with an experimental study and molecular dynamics simulations
- (2020) Hana Jung et al. Scientific Reports
- Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM
- (2020) Anders Boyd et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan
- (2020) Pin-Nan Cheng et al. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
- 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations
- (2020) Ming-Lung Yu et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Cure or curd: Modification of lipid profiles and cardio‐cerebrovascular events after hepatitis C virus eradication
- (2020) Chung‐Feng Huang et al. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
- Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection
- (2020) Amy Puenpatom et al. Infectious Diseases and Therapy
- Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
- (2020) Chung-Feng Huang et al. Clinical and Molecular Hepatology
- Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets
- (2019) Nathalie Alazard-Dany et al. Viruses-Basel
- Association of Hepatitis C and B Virus Infection with CKD and Impact of Hepatitis C Treatment on CKD
- (2019) Hui Zhang et al. Scientific Reports
- Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment
- (2019) Luzelena Caro et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Transplanting hepatitis C virus–infected hearts into uninfected recipients: A single‐arm trial
- (2019) Rhondalyn C. McLean et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia
- (2019) Zobair M. Younossi et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update
- (2019) Elise J. Smolders et al. CLINICAL PHARMACOKINETICS
- An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions
- (2019) Chung-Feng Huang et al. JOURNAL OF INFECTIOUS DISEASES
- Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients
- (2019) Ann E. Woolley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis
- (2019) Ira M. Jacobson et al. Clinical and Translational Gastroenterology
- Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial
- (2019) Yi-Chun Lin et al. Infection and Drug Resistance
- Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial
- (2019) Anne Boerekamps et al. Lancet Gastroenterology & Hepatology
- Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A single‐centre experience
- (2019) Lennert Fransen et al. HAEMOPHILIA
- Real world experience with Grazoprevir/Elbasvir in the treatment of previously “difficult to treat” patients infected with HCV genotype 1 and 4
- (2019) Dorota Zarębska‐Michaluk et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan
- (2019) Tzu‐Cheng Tsai et al. JOURNAL OF MEDICAL VIROLOGY
- Hepatitis C
- (2019) C Wendy Spearman et al. LANCET
- Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial
- (2019) Marcelo Cypel et al. Lancet Respiratory Medicine
- Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population
- (2019) Debra T. Choi et al. ANTIVIRAL RESEARCH
- Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus–Infected Donors to Noninfected Recipients
- (2018) Christine M. Durand et al. ANNALS OF INTERNAL MEDICINE
- Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial
- (2018) Graham R. Foster et al. HEPATOLOGY
- High efficacy and safety of grazoprevir and elbasvir for 8 weeks in treatment-naive, non-severe fibrosis HCV GT1b-infected patients: Interim Results of the STREAGER Study
- (2018) A. Abergel et al. JOURNAL OF HEPATOLOGY
- Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection
- (2018) Johannes Vermehren et al. JOURNAL OF HEPATOLOGY
- The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C
- (2018) Po-Cheng Liang et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study
- (2018) A. Brown et al. JOURNAL OF VIRAL HEPATITIS
- Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis
- (2018) Tarik Asselah et al. LIVER INTERNATIONAL
- Management of acute HCV infection in the era of direct-acting antiviral therapy
- (2018) Marianne Martinello et al. Nature Reviews Gastroenterology & Hepatology
- The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C
- (2018) Batbold Batsaikhan et al. Oncotarget
- Twelve-Month Outcomes After Transplant of Hepatitis C–Infected Kidneys Into Uninfected Recipients
- (2018) Peter P. Reese et al. ANNALS OF INTERNAL MEDICINE
- Kidney Function Decline in Patients with CKD and Untreated Hepatitis C Infection
- (2018) Sara Yee Tartof et al. Clinical Journal of the American Society of Nephrology
- Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study
- (2018) Masanori Atsukawa et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: results from the Spanish HEPA-C real-world cohort
- (2018) M. Hernández-Conde et al. JOURNAL OF VIRAL HEPATITIS
- The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment
- (2018) Christian Qvigstad et al. MEDICINE
- Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
- (2018) Sylvia Drazilova et al. Canadian Journal of Gastroenterology and Hepatology
- Decline of Increased Risk Donor Offers on Waitlist Survival in Heart Transplantation
- (2018) Michael S. Mulvihill et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis
- (2018) Lawrence Serfaty et al. JOURNAL OF VIRAL HEPATITIS
- Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection
- (2017) Paul Kwo et al. GASTROENTEROLOGY
- The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection
- (2017) Parag Mahale et al. GUT
- Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study
- (2017) Christophe Hézode et al. HEPATOLOGY
- Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study
- (2017) Tai-Shuan Lai et al. HEPATOLOGY
- Hepatitis C treatment from “response-guided” to “resource-guided” therapy in the transition era from interferon-containing to interferon-free regimens
- (2017) Ming-Lung Yu JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients
- (2017) David S. Goldberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review
- (2017) Louisa Degenhardt et al. Lancet Global Health
- Long term survival in persons with hemophilia and chronic hepatitis C: 40 year outcomes of a large single center cohort
- (2016) M. Elaine Eyster et al. AMERICAN JOURNAL OF HEMATOLOGY
- Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy
- (2016) Gregory J. Dore et al. ANNALS OF INTERNAL MEDICINE
- The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons
- (2016) Frederick C. Lahser et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of antiviral therapy for HCV on lipid levels
- (2016) Stefan Mauss et al. ANTIVIRAL THERAPY
- Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment
- (2016) Elise J. Smolders et al. DRUG SAFETY
- Elbasvir/Grazoprevir: First Global Approval
- (2016) Gillian M. Keating DRUGS
- Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial
- (2016) Eric Lawitz et al. HEPATOLOGY
- Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study
- (2016) Tung-Hung Su et al. HEPATOLOGY
- Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection
- (2016) Chandana Papudesu et al. Hepatology International
- The risk of coronary artery disease and cerebrovascular disease in patients with hepatitis C: A systematic review and meta-analysis
- (2016) Pasquale Ambrosino et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study
- (2016) Hiromitsu Kumada et al. JOURNAL OF GASTROENTEROLOGY
- HCV epidemiology in high-risk groups and the risk of reinfection
- (2016) Håvard Midgard et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial
- (2016) Jan Sperl et al. JOURNAL OF HEPATOLOGY
- Recent Advances in Antiviral Therapy for Chronic Hepatitis C
- (2016) Akihiro Tamori et al. MEDIATORS OF INFLAMMATION
- Genotype specific peripheral lipid profile changes with hepatitis C therapy
- (2016) Mark R Pedersen et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Hepatitis C virus relies on lipoproteins for its life cycle
- (2016) Germana Grassi WORLD JOURNAL OF GASTROENTEROLOGY
- Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection
- (2015) Stefan Zeuzem et al. ANNALS OF INTERNAL MEDICINE
- Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE: Table 1.
- (2015) Maria Buti et al. CLINICAL INFECTIOUS DISEASES
- Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection
- (2015) Adriaan J van der Meer GUT
- Chronic hepatitis C infection is associated with insulin resistance and lipid profiles
- (2015) Chia-Yen Dai et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent
- (2015) Xavier Forns et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
- (2015) Mark Sulkowski et al. LANCET
- Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
- (2015) David Roth et al. LANCET
- Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial
- (2015) Jürgen K Rockstroh et al. Lancet HIV
- Hepatitis C Virus Infection among Injection Drug Users with and without Human Immunodeficiency Virus Co-Infection
- (2014) Meng-Hsuan Hsieh et al. PLoS One
- Hepatitis C Virus Infection Increases Risk of Developing End-Stage Renal Disease Using Competing Risk Analysis
- (2014) Jia-Jung Lee et al. PLoS One
- Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant
- (2014) H.-H. Hsiao et al. Transplant Infectious Disease
- Hepatitis C virus NS5A inhibitors and drug resistance mutations
- (2014) Shingo Nakamoto WORLD JOURNAL OF GASTROENTEROLOGY
- Discovery of MK-8742: An HCV NS5A Inhibitor with Broad Genotype Activity
- (2013) Craig A. Coburn et al. ChemMedChem
- Computational Study on the Drug Resistance Mechanism against HCV NS3/4A Protease Inhibitors Vaniprevir and MK-5172 by the Combination Use of Molecular Dynamics Simulation, Residue Interaction Network, and Substrate Envelope Analysis
- (2013) Weiwei Xue et al. Journal of Chemical Information and Modeling
- Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890
- (2013) Christophe Hézode et al. JOURNAL OF HEPATOLOGY
- Meta-analysis of observational studies: hepatitis C and survival after renal transplant
- (2013) F. Fabrizi et al. JOURNAL OF VIRAL HEPATITIS
- MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants
- (2012) Vincenzo Summa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Treatment of acute HCV infection
- (2011) Jason Grebely et al. Nature Reviews Gastroenterology & Hepatology
- Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel
- (2011) Laurent Chatel-Chaix et al. Viruses-Basel
- Association of Hepatitis C and B Virus Infection With CKD in an Endemic Area in Taiwan: A Cross-sectional Study
- (2010) Jia-Jung Lee et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Underutilization of Hepatitis C-Positive Kidneys for Hepatitis C-Positive Recipients
- (2010) L. M. Kucirka et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Meta‐Analysis: Increased Mortality Associated with Hepatitis C in HIV‐Infected Persons Is Unrelated to HIV Disease Progression
- (2009) Ting‐Yi Chen et al. CLINICAL INFECTIOUS DISEASES
- Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: A community-based study
- (2008) Chia-Yen Dai et al. JOURNAL OF HEPATOLOGY
- Acute hepatitis C
- (2008) Anurag Maheshwari et al. LANCET
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now